Travis Murdoch, HI-Bio CEO
November 1, 2022 06:14 AM EDTUpdated 12:40 PM
Financing
Startups

That se­cre­tive ARCH biotech with two an­ti­bod­ies from Mor­phoSys? It’s now got $120M

Lei Lei Wu

News Reporter

In June, HI-Bio, short for Hu­man Im­munol­o­gy Bio­sciences, li­censed two can­di­dates from Ger­man biotech Mor­phoSys — felzartam­ab for two au­toan­ti­body kid­ney dis­eases, and HIB210, which goes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times